Blog Archive
-
▼
2008
(233)
-
▼
February
(16)
- DiaMedica, DM-99 Shown to Improve Glucose Metaboli...
- Bentley Pharmaceuticals, Phase II India clinical s...
- Zealand Pharma, Phase III program for AVE0010/ZP10
- ConjuChem, Phase II Study of PC-DACTM:Exendin-4
- InteKrin Therapeutics' INT131, Phase IIb study in ...
- Lilly , KwikPen for Humalog and Humalog Mixtures
- Kinetic Concepts, V.A.C.Therapy to be More Efficac...
- t+ Medical, Alliance with Lifescan, Inc. to improv...
- Lipomics Technologies, Insulin Resistance Research...
- Biovail , Canadian Commercial Availability of 1,00...
- Geron, Second U.S. Patent for Production of Pancre...
- DiaKine Therapeutics’ Anti-Inflammatory Drugs
- Healthcare Providers Direct, First Accurate and Ef...
- Novagali Pharma, FDA Clearance of IND for US Clini...
- Immunosyn, First Phase “Proof of Concept Trial” in...
- Genaera, Diabetes IND In Effect for Trodusquemine ...
-
▼
February
(16)
Monday, February 25, 2008
Kinetic Concepts, V.A.C.Therapy to be More Efficacious Than Advanced Moist Wound Therapy in Treating Diabetic Foot Ulcers
February 11, 2008 - -Kinetic Concepts, Inc. (NYSE:KCI) announced the final efficacy results of a randomized controlled clinical trial (RCT) on the clinical efficacy of KCI’s V.A.C.® System negative pressure wound therapy (NPWT) compared to advanced moist wound therapy (AMWT) to treat diabetic patients with foot ulcers. The study, which showed that V.A.C. Therapy is more efficacious than AMWT in the treatment of diabetic foot ulcers, will be published in the April 2008 issue of Diabetes Care, the peer-reviewed journal of the American Diabetes Association... Kinetic Concepts' Press Release -